ArticleFrontiers in endocrinology2025
Development and externally validated prediction model of individualization of FSH starting dose in the depot GnRH agonist protocol for the early follicular phase.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Each controlled ovarian hyperstimulation(COH) protocol has its own unique mechanism and hormone pattern. The depot GnRHa protocol has a deeper down-regulation effect and favorable clinical pregnancy rates. The predictive model of the optimal follicle-stimulating hormone (FSH) starting dose in the early follicular phase depot GnRH agonist (EFDGa) protocol has not been reported. Our study was made to explore predictive indicators for determining the optimal FSH starting dose in patients undergoing ovarian stimulation with the EFDGa protocol in assisted reproductive technology (ART), and to develop and validate a nomogram prediction model for the starting dose of FSH. Methods: This retrospective study included 2733 cycles who underwent fresh cycle transplantation at two large teaching hospitals in China from January to December 2022: center 1 (Reproductive Medicine Center of first affiliated Hospital of Zhengzhou University) provided the data for modelling (n = 938) and internal testing (n = 400), and center 2 (Reproductive Medicine Center of Jiangxi Maternal and Child Health Hospital) provided the data for external testing (n = 1109). Patient demographics, including age, anti-Mullerian hormone (AMH) levels, baseline endocrine profile, and body mass index (BMI), along with information on ovulation stimulation, were collected. Univariate and multivariate linear regression models were used to identify factors influencing the FSH starting dose. A nomogram for the ideal FSH starting dose was developed based on these factors and validated internally and externally. Bland and Altman plots and paired t-tests were conducted to verify the concordance between groups. Results: Multivariate analysis revealed that patient age, BMI, basal FSH, AMH, and antral follicle count (AFC) were indicators of FSH starting dose. The regression model for predicting FSH starting dose was determined as: Initial FSH dose = 62.957 + 1.780*AGE(years) +4.927*BMI (kg/m²) +1.417*bFSH (IU/ml) - 1.996*AFC - 48.174*AMH (ng/ml). Bland and Altman analysis showed good agreement in the internal validation (bias: 0.583, SD of bias: 33.07IU, 95%LOA: -69.7 to 68.5IU b). Furthermore, validating the model on external cohort (center 2) confirmed that nomogram prediction model is an accurate predictor of FSH starting dose ((bias: -1.437, SD of bias: 38.28IU; 95%LOA: -80.0 to 77.1IU). Conclusions: We established a model for effectively predicting the ideal FSH starting dose, with the nomogram model providing an intuitive representation of the data. The predictive model demonstrates practical utility, effectively initiating a proper ovarian response and preventing adverse ovarian reactions or the occurrence of ovarian hyperstimulation syndrome. As more IVF cycles are being generated in the future, this model will be valuable in clinicians using basic parameters to assess proper initial dose of FSH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.